International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 4, April 2025 **ijppr.humanjournals.com** ISSN: 2349-7203

Enhancing the Solubility of Glipizide: Strategies for Improving Bioavailability in BCS Class II Drugs

Sanskruti Talele*[1], Pratiksha Nathe[1], Sakshi Bacchav[1], Pranav Pajai[1], Vedant Thakare[1], Ms. Sonali Patil[2], Dr. M.R.N Shaikh[3]

[1*] Student Department of Pharmaceutical Chemistry MET Institute of D. Pharmacy, Adgaon, Nashik, Maharashtra, India.
[2] Assistant Professor Department of Pharmaceutical Chemistry, MET Institute of D. Pharmacy, Adgaon, Nashik, Maharashtra, India
[3] Principal MET Institute of D. Pharmacy, MET Institute of D. Pharmacy, Adgaon, Nashik, Maharashtra, India

Received: 2025-4-05 Revised: 2025-4-17 Accepted: 2025-4-25

ABSTRACT

Glipizide, a second-generation sulfonylurea, is an effective oral hypoglycemic agent for type 2 diabetes. However, its poor aqueous solubility limits bioavailability and therapeutic consistency. Conventional approaches like micronization and solid dispersion improve dissolution but face stability challenges. Advanced techniques such as nanotechnology, cocrystallization, cyclodextrin complexation, and lipid-based formulations enhance solubility and absorption. Additionally, novel formulations like oral dispersible tablets improve patient compliance. Regulatory considerations, including stability testing and bioequivalence, play a crucial role in formulation success. Enhancing glipizide's solubility is essential for optimizing its therapeutic efficacy and ensuring consistent glucose control in diabetic patients.

Keywords: Glipizide, Solubility enhancement, Oral hypoglycemic agents, Nanotechnology, Cyclodextrin complexation, Bioavailability improvement

1. INTRODUCTION

A sulfonylurea of the second generation, glipizide is mainly used to treat type 2 diabetes mellitus. Its essential function is due to the presence of a sulfonylurea moiety in its chemical structure. Its pharmacological effect is due to a ketone group, which is attached to two aromatic rings by a sulfonylurea group in the chemical structure. Glipizide's chemical name is 1[[p [2(2oxopropyl) phenyl] sulfonic] phenyl] urea, and its chemical formula is C21H27N5O4S. [1]

Glipizide is a Class II medicine according to the Biopharmaceutics Classification System (BCS), which indicates that it is highly permeable but poorly soluble. Dissolution rate can be the rate-limiting phase in drug absorption for BCS Class II medications. To improve glipizide's dissolving rate, increase bioavailability, and eventually achieve safer and more efficient blood glucose management at lower doses, solubility enhancement becomes a critical step in the formulation process. Poor solubility is a particularly difficult issue as it not only impacts glipizide absorption but also causes unpredictable clinical results. This may require more frequent or larger doses, which raises the possibility of side effects including hypoglycemia. Thus, increasing glipizide's solubility may increase its therapeutic efficacy, reduce patient response variability, and provide longer-lasting pharmacological effects. [1, 2] Numerous approaches have been developed to address glipizide's solubility issues. They consist of both standard and innovative medicinal methods. To increase the rate at which poorly soluble medications dissolve, standard methods like micronization (particle size reduction) and solid dispersion formulations have been frequently used. These techniques fulfill the solubility requirements, however, frequently have drawbacks, such as complicated manufacturing procedures or physical instability. [1, 2, 3]

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 4, April 2025 ijppr.humanjournals.com ISSN: 2349-7203



Fig 1.1 Mechanism of Action of Glipizide

1.1 Therapeutic Use:

- The main purpose of glipizide is to treat type 2 diabetes mellitus.
- It does this through increasing the production of insulin by pancreatic beta cells, which lowers blood glucose levels.
- In place of insulin, which is given to the body directly, glipizide helps the body to release insulin naturally in response to glucose.
- It also slightly improves insulin sensitivity and lowers the amount of glucose produced by the liver.

Figure 1.2: Importance of Clinical practices [2-8]

1.2 Factors affecting Bioavailability of glipizide:

- **Low Solubility:** Due to its poor gastrointestinal dissolution caused by its low aqueous solubility, glipizide's absorption as well as its bioavailability may be reduced. A very small portion of the dose that is given enters the systemic circulation. For example, glipizide has a low solubility, which results in a bioavailability of roughly 1020% when taken orally. [5]

- **Changes in Plasma Levels:** Glipizide's unequal and poor bioavailability can lead to unequal plasma drug levels. Changes in the drug's effectiveness in regulating blood glucose levels may result in less-than-ideal treatment effects. [9]

- **Variable Absorption**: Glipizide's low solubility causes uneven absorption in various persons, which can lead to varying plasma amounts and uneven bioavailability. This affects how well it works as a medication to keep blood glucose levels steady.[5]

- **First-Pass Metabolism**: Glipizide has high hepatic first-pass metabolism following absorption, which further lowers the quantity of medication that enters the systemic circulation and adds to plasma level fluctuations.[5]

- **Food Effect**: Glipizide absorption can be slowed down and peak plasma concentrations can be decreased when taken with food. This can lead to unstable blood levels and less continuous glucose control.[9]

- **Dosage Form**: The rate of dissolution and absorption depends on by the formulation (e.g., immediate vs. extended-release), which changes bioavailability and causes variations in plasma drug levels.

- **GI Factors:** Glipizide absorption is influenced by the pH, motility, and move of gastric emptying in the intestines, which further varies the plasma level of the drug.

Figure No 1.3: Objectives [10-12]

1.3 Methods consist of:

- **Solid dispersions:** To improve dissolving rates and bioavailability, this technique disperses the medication in a carrier matrix.

- **Particle size reduction:** Drug particles are made smaller by methods like micronization and nanonization, which increases the surface area available for dissolving.

- **Similar structures:** Glipizide's solubility is increased by complexing it with cyclodextrins or other solubilizing agents, which increases the drug's rate of dissolution. [11]

1.4 Advanced Delivery Systems and Nanotechnology:

An original method for improving solubility is provided by nanotechnology-based solutions:
Faster drug absorption and improved bioavailability are made possible by the large surface area and dissolving rates of nanoparticles and nanocrystals.

- **Lipid-based formulations:** There is potential to improve solubility and absorption using liposomes, lipid nanoparticles, and self-emulsifying drug delivery systems (SEDDS).[13]

- **Regulatory Considerations:** New formulations must be developed in according to safety, efficacy, and stability standards. This involves carrying out demanding preclinical and clinical research to make sure the solubility-enhanced medication keeps its intended therapeutic profile. During the stages of formulation development and testing, the Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) standards are applicable.
Regulators such as the FDA and EMA require stability testing, bioequivalence tests, and in vitro in vivo correlation (IVIVC).[14]

- **Application in Personalized Medicine:** Solubility enhancement can also be customized for uses in personalized medicine, enabling the modification of medication formulations in response to patient-specific variables like age, medical conditions, or metabolic rates.

Oral dispersible tablets (ODTs) and customized dosage forms are examples of advanced drug delivery systems that can improve the efficacy and convenience of therapies for patients with needs.[15]

- **Research and Development:** There are a variety of research possibilities in the pharmaceutical sciences due to the continuous study of novel methods for improving solubility. Research focused on novel materials, innovative drug delivery systems, and biopharmaceutical prediction to forecast and improve the efficacy of poorly soluble medications such as glipizide. Research collaborations between universities and pharmaceutical businesses are still the source of new developments in solubility improvement techniques.[16]

1.5 Overview

1. Reduction of Particle Size Methods:

Micronization is the process of that use mechanical tools, like milling or jet grinding, to reduce the particle size of glipizide to the micron level, which is usually 110 µm. The aim is to raise the surface area since this accelerates the drug's rate of disintegration.

2. Nanoparticle Formulation: Nanoparticle formulations significantly improve solubility and dissolution by increasing surface area by further lowering the particle size to the nanometer range (100–1000 nm). Methods such as solvent evaporation, wet milling, and high-pressure uniformity can be used to create nanoparticles.

Effects on Solubility:

The drug's surface area is increased via micronization, leading to faster rates of solubility and increased bioavailability. Agglomeration or recrystallisation of micronized particles, however, may restrict this method and eventually decrease the solubility gain. The process of formulating nanoparticles not only improves surface area but also modifies crystallinity and surface energy, greatly improving the solubility of medications that are not very water soluble, such as glipizide. Compared to micronized particles, nanoparticles have improved stability and solubility due to their reduced aggregation ability. Compared to micronized particles, nanoparticles have improved stability and solubility due to their reduced aggregation ability. [17]

2. Solid Forms and Polymorphs:

Multiple Glipizide Polymorphs: Polymorphs are different crystalline forms of the same substance. Like many medications, glipizide can exist in a variety of polymorphic forms, each of which may have unique stability and solubility traits. Due to variations in molecular arrangement and lattice energy, each polymorph has a different solubility. In general, the more stable (thermodynamic) forms have lower solubility but higher stability, while the less stable (metastable) polymorphs have higher solubility but lower stability.

The effect on stability and solubility

Solubility: Although metastable polymorphs require less energy to break their molecular bonds, they typically have higher solubility. But with time, they might change into a more stable polymorph, which would make them less soluble.
Stability: Although the stable polymorph is less soluble, it provides better stability for a longer duration of time in storage, lowering the possibility of phase transitions and recrystallisation during production or shelf life.[18]

3. Cocrystal

Cocrystal Formation Using Several Conformers: Cocrystals are crystalline formations made up of two or more constituents, usually an alcohol, glipizide, or another active pharmaceutical ingredient (API) and a conformer, which is a chemical that is approved for use in pharmaceuticals. These are noncovalent interactions that alter the physicochemical characteristics of the API, like hydrogen bonding.
Glipizide cocrystals develop by choosing appropriate conformers (nicotinamide, saccharin, etc.) that increase solubility without risking the stability of the medication. Cocrystal formation modifies the intermolecular interactions and lowers the crystal lattice energy to increase the rate of dissolution.

2. IMPACT ON SOLUBILITY AND RATE OF DISSOLUTION:

Solubility: By changing glipizide's solid-state characteristics, cocrystals can greatly increase its solubility. They form a brand-new crystalline structure that dissolves more easily in water conditions.
Dissolution Rate: Compared to pure crystalline counterparts, cocrystals often have faster dissolution rates due to changes in crystal packing and a reduction in lattice energy. The solubility of the conformer employed and the API both affect the solubility of cocrystals.
Stability: While maintaining enhanced solubility, cocrystals frequently show greater stability than metastable polymorphs. They are a possible alternative for long-term storage because they are also more stable than amorphous forms.[19]

1. Salt Formation

Creation of Glipizide Salts:

Drugs that are poorly soluble in water can often be made more soluble by using the right acids or bases to convert the medication into its salt form. Salt production is difficult with glipizide since it belongs to the sulfonylurea class of drugs, which is slightly acidic in nature. Glipizide does not have the strong basic or acidic sites required for the simple production of salts, in contrast to medications containing ionizable amine groups. Although there are not many glipizide salt forms, researchers have investigated alternative modifications to increase its solubility instead of classical salt production, such as cocrystallization and amorphous solid dispersions.

Effect on Solubility: When salt production is possible, it can greatly increase solubility through:

Increasing ionization: A drug's solubility is increased when it is in a salt form because it ionizes more readily in water.
Faster dissolution: A salt that has been ionized dissolves more quickly than a medication that has been neutralized.
Increasing bioavailability: Improved solubility corresponds to increased therapeutic efficacy and absorption. Because glipizide has a weak acidity, other methods such as cocrystallization with excipients are usually investigated instead of traditional salt production.

2. Complexation

Use of Cyclodextrins and Other Complexing Agents:

The common technique of complexation with molecules such as cyclodextrins (CDs) is used to increase the solubility of poorly soluble medications such as glipizide. Cyclodextrins are oligosaccharides that are cyclic and have an interior hydrophobic chamber and an outer hydrophilic surface. The hydrophobic core of cyclodextrins may contain medications with low aqueous solubility, like glipizide, increasing the drugs' apparent solubility in water.

3. THE CYCLODEXTRIN COMPLEXATION MECHANISM:

Inclusion Complexes: The hydrophilic surface of cyclodextrins interacts with the aqueous environment to enhance the medication's solubility while encasing the hydrophobic portion of the drug within their cavity.
Hydrophilic Exterior: This enhances the medication's water solubility, inhibiting aggregation and lowering crystallization.

Enhanced solubility: As a result of dispersing in an aqueous media, the encapsulated medication exhibits a marked increase in solubility.
Increased dissolution rate: Because the drug's complexed form is easier for the gastrointestinal tract to absorb, the drug's solubility profile is improved. Better solubility and dissolution result in increased bioavailability, which can lead to improved therapeutic efficacy at lower doses. [20, 21–22]

- **Glipizide Beta cyclodextrin Complex:** Glipizide's solubility was significantly increased when it was complexed with beta cyclodextrin (βCD) utilizing methods like kneading and coprecipitation, according to a 2003 study by Chowdary et al. The formation of an inclusion complex resulted in a considerable increase in the solubility and dissolution rate of glipizide in the presence of βCD, as per the study findings.[20]

- **Glipizide Hydroxypropyl Beta Cyclodextrin Complex:** It was found in a different study that glipizide can form complexes with hydroxypropyl beta cyclodextrin (HPβCD). Compared to natural βCD, HPβCD is a chemically modified cyclodextrin that has better solubilization qualities. According to the study, glipizide's solubility, dissolution, and bioavailability were all improved by HPβCD complexes.[23]

- **Other Complexing Agents:** In addition to cyclodextrins, polyvinylpyrrolidone (PVP) and poloxamers have also been used as complexing agents to produce solid dispersions or amorphous complexes, which have been shown to increase glipizide's solubility. These substances improve the drug's dispersion in water and stop it from crystallizing.[22]

4. FORMULATION APPROACHES

1. Dispersions

Methods:

Melt Extrusion: This method involves combining a drug and a polymeric carrier, heating the mixture until it melts, then expanding the molten mixture into a solid form and cooling it down. This process disperses the drug molecules in the polymer matrix, increasing the solubility of poorly soluble drugs like glipizide by dispersing them at a molecular level, frequently in an amorphous form. Solvent Evaporation: This method involves dissolving the drug and polymer in a volatile solvent, then removing the solvent to leave behind a solid dispersion. Since it does not involve heat, it is especially helpful when thermal degradation is a concern.

Impact on Release and Solubility:

Solubility: Poorly water-soluble drugs become much more soluble in solid dispersions, especially when the drug is in an amorphous state. The drug's molecular dispersion in the polymeric carrier improves solubility by increasing wettability and decreasing particle size.
Release: As the polymer dissolves and permits the drug to disperse in the gastrointestinal fluid, the dispersion of the medication in a hydrophilic carrier guarantees a quicker and more even release of the medication. Better absorption results from a higher dissolution rate resulting from it.[11]

Nanotechnology

Nanocrystals:

Nanocrystals are essentially pure drug particles that have been reduced to nanoscale sizes, usually between 100 and 1000 nm. The surface area to volume ratio rises because of the significant fall in particle size, increasing solubility and dissolution rate.

Production Techniques: Precipitation, wet milling, and high-pressure uniformity are commonly utilized techniques. Nanocrystals can be prepared into solid dosage forms or stabilized in a solution.

Nano emulsions: These are water, oil, and surfactant-based submicron-sized emulsions, usually with a diameter of 20200 nm. These systems disperse lipophilic medications, such as glipizide, in the emulsion's oil phase, increasing their solubility. High-energy techniques like ultrasonication and high-pressure uniformity, as well as low-energy techniques like phase inversion, can be used to create nano emulsions. They serve as a drug's reservoir, guaranteeing a steady release and enhancing its bioavailability.

Benefits: Without the need for solubilizing chemicals, nanocrystals improve absorption, bioavailability, and dissolution rates. They are especially useful for medications that have low permeability and solubility (BCS Class II and IV medicines).

Nano emulsions: They provide long-lasting drug release and increase the solubility of hydrophobic medications. Also, nano emulsions provide a high level of physical stability.

Challenges:

Nanocrystals: Specialized equipment is needed for the intricate formulation process. Particle aggregation and the requirement for stabilizing chemicals to stop crystal formation are further possible problems.

Nano emulsions: They can be irritating or poisonous, therefore choosing the right surfactants and cosurfactants is important. Furthermore, as phase separation or combination of droplets may eventually occur, the stability of nano emulsions may provide a problem.[13]

2. Liposomes and Nanoparticles

Formulation Techniques: Liposomes are a type of spherical vesicle with an aqueous core surrounded by lipid bilayers. Drugs that are hydrophilic or hydrophobic can be contained in liposomes. The hydrophobic part of the liposome bilayer can aid in glipizide's improved solubility.

Production Techniques: Solvent evaporation, thin-film hydration, and reverse-phase evaporation are frequently used techniques to prepare liposomes.

Polymeric nanoparticles: These can encapsulate medications to increase their solubility. They are composed of biodegradable polymers like polylactic acid (PLA) or poly (lactic glycolic acid) (PLGA). The bioavailability of drugs such as glipizide can be increased by containing them within or absorbing them onto the surface of the nanoparticles.

Production Methods: Methods such as emulsion diffusion, solvent evaporation, and nano precipitation are used to produce nanoparticles.

5. SOLUBILITY IMPROVEMENT:

Liposomes: By wrapping hydrophobic medications like glipizide in a lipid matrix, liposomes' lipid bilayer improves their solubility and allows better dispersion in aqueous settings. Also, liposomes improve medication stability and allow targeted drug delivery to regions.

Polymeric nanoparticles: By wrapping weakly soluble medications in a polymer matrix, nanoparticles increase the rate of dissolution and increase their solubility. Better dispersion in biological fluids is made possible using hydrophilic polymers.

Advantages:

Liposomes: These can enhance drug stability, lessen toxicity, and target drug delivery. As liposomes may contain both hydrophilic and hydrophobic medications, a variety of drug delivery methods are possible. Polymeric nanoparticles provide controlled drug release, improve drug solubility, and improve drug stability. Because they degrade naturally, there is less chance of toxicity.

Problems:

Liposomes: The production of liposomal formulations can be expensive, and there are stability issues with lipid oxidation and medication leakage from the capsule.

Nanoparticles: Complex procedures are needed to produce polymeric nanoparticles, and problems with particle aggregation or drug loading capacity can occur.[24]

6. OTHER APPROACHES IN ENHANCING SOLUBILITY:

1. Surfactants and Solubilizers

Role in Enhancing Solubility:

To increase the solubility of weakly soluble substances in aqueous systems, surfactants and solubilizes are frequently utilized. These amphiphilic molecules can interact with hydrophobic solutes as well as water because they have both hydrophilic (polar) and hydrophobic (nonpolar) sections.

Mechanism of Action:

Micellization: Surfactants aggregate to form micelles above a concentration known as the critical micelle concentration (CMC). These micelles have a hydrophobic core that can be used to solubilize hydrophobic solutes, and an outside that is hydrophilic interacts with water to increase solubility.

Reduction of Surface and Interfacial Tension: Surfactants facilitate the solute's easier dispersion in the aqueous medium by reducing the surface tension between the hydrophobic solute and water.

2. Hydrotropy

Principles: The method called hydrotropy occurs when a hydrotropic agent is added in large concentration and it causes a poorly soluble chemical to become much more soluble in water. Hydrotropes interact with solute molecules by noncovalent interactions such hydrogen bonding and stacking, as opposed to surfactants, which create micelles.

Mechanism of Action:

Hydrotrope-Solute Interaction: By forming into weak complexes or networks around the solute, hydrotropes help in the solubility of hydrophobic substances.

Water Structure Alteration: Hydrotropes cause hydrophobic molecules' water structure to change, which lowers the solubilization energy barrier and encourages a more uniform solute distribution.

Common Hydrotropes: Benzoate sodium, Salicylate of sodium, Sodium xylene sulfonate with urea

Applications in Pharmaceuticals: Without the use of organic solvents or surfactants, hydrotropy is used to increase the solubility of medications with limited water solubility.

Hydrotropes are used in industrial cleaning solutions to dissolve oils and greases.

Applications in the Environment: Hydrotropes can be used to remove contaminants that are hydrophobic from soil and water.[26]

Novel Techniques and Technologies [27, 28, 29]

Recently, several new techniques have been developed to improve the solubility of drugs that are not very water soluble, such as glipizide. Enhancing bioavailability, dissolving rates, and formulation stability is the goal of these technologies.

7. NEW APPROACHES AND INNOVATIONS

Drug particles are reduced to nanoscale size using the nanocrystal technology, which increases their surface area and rate of dissolution. It is possible to create nanocrystals with the use of high-pressure uniformity or milling. Glipizide nanocrystals have been linked to improved solubility and bioavailability, based on studies.

By providing the medication in an amorphous state—which is more soluble than the crystalline form—into a polymer matrix, Amorphous Solid Dispersions (ASDs) improve solubility. To create stable, amorphous forms of glipizide, polymers such as hydroxypropyl methylcellulose, or HPMC, are commonly utilized.

1. **Lipid-Based Formulations:** Lipid-based systems increase the solubility of lipophilic medications like glipizide. Examples of these systems include self-emulsifying drug delivery systems (SEDDS) and nano emulsions. These systems create fine emulsions during digestion that improve medication absorption.

2. **Supercritical Fluid Technology:** This technique dissolves poorly soluble medications by dissolving them in supercritical CO2, resulting in small particles that dissolve rapidly. It has been demonstrated that glipizide treated with supercritical fluids exhibits enhanced dissolving properties.

3. **Cocrystallization:** To increase a drug's solubility and stability, conformers and drugs are combined to produce cocrystals. Research has indicated that the water solubility of glipizide cocrystals with conformers such as saccharin is enhanced.

Potential Impact on Future Formulations

Future drug formulations could be completely changed by these cutting-edge methods, particularly for Class II drugs (glipizide) under the Biopharmaceutics Classification System (BCS). Increased solubility is expected to lead to improved bioavailability and reduced dosage needs, which will help in the creation of more effective drug delivery methods such transdermal patches and long-acting injectables.

8. CASE STUDIES

Many studies have successfully showcased the use of these solubility-enhancing techniques for improving glipizide formulations.

1. Nanocrystals: glipizide nanocrystals were prepared by Patel et al. (2016) using high-pressure uniformity, which resulted in an important rise in solubility and dissolution rate over raw glipizide.
2. Amorphous Solid Dispersions (ASDs): To increase the solubility and bioavailability of glipizide, Shah et al. (2018) explored the usage of HPMC based autism spectrum disorders (ASD) The study found that this strategy worked well to increase the drug's rate of solubility.
3. Lipid-Based Formulation: A self-nanoemulsifying drug delivery system (SNEDDS) for glipizide was created by Sharma et al. (2020). The formulation demonstrated enhanced bioavailability and quick dissolution, showing potential for use in clinical settings in the future.

These case studies illustrate the successful application of modern solubility enhancing techniques to improve glipizide's formulation and performance **[30-34]**.

Conclusion

This study identifies several important methods for increasing drug solubility, which is necessary to raise therapeutic efficacy and bioavailability. By increasing the drug's surface area through micronization and nanonization, particle size reduction improves solubility rates. Fenofibrate serves as an example of how solid dispersion systems, in which medications are distributed in carriers, greatly increase solubility. To increase solubility, cyclodextrin complexation creates inclusion complexes with hydrophobic medications like ketoconazole. Cyclosporine is one example of how self-emulsifying drug delivery systems (SEDDS) produce microemulsions that improve solubility. Prodrug strategies, such as the chemical modification of Val acyclovir, increase a drug's solubility and permeability.

Future research needs to concentrate on nanotechnology, examining unique nanoparticles and nanocarriers for creative solubility solutions. Applying novel polymers and carriers, advances in solid dispersion techniques may improve drug stability and solubility even more. Treatment effects may be maximized by specific methods of solubility an increase based on patient-specific factors. Developing smart drug delivery systems that release pharmaceuticals under predetermined conditions, combining multiple solubility methods to create synergistic effects, and expanding sustainable manufacturing procedures to cut costs are some potential enhancements. Due to the chance for these advancements to greatly improve therapeutic efficacy and drug delivery, solubility growth is an essential field for ongoing study and development.

REFERENCES:

1. Indian Pharmacopeia Commission. Indian Pharmacopeia.8th Edition. Ghaziabad: IPC; Year 2014
2. Nathan, D. M., Buse, J. B., Davidson, M. B., et al. (2009). "Medical management of type 2 diabetes: a clinical practice guideline." *Diabetes Care*, 32(Supplement 1), S1S77. doi:10.2337/dc09S001

3. Goodman, L. S., & Gilman, A. (2021). "Goodman & Gilman's: The Pharmacological Basis of Therapeutics." McGraw-Hill Education. ISBN: 9781264257878
4. American Diabetes Association. (2023). "Standards of Medical Care in Diabetes—2023." *Diabetes Care*, 46(Supplement 1), S1S291. doi:10.2337/dc23S001
5. Patel, S., & Patel, M. (2011). Formulation and Evaluation of Glipizide Microemulsion for Oral Delivery. International Journal of Pharmaceutical Sciences and Research, 2(10), 25662574.
6. Jain, S. K., & Agarwal, A. (2009). Development of a sensitive oral drug delivery system for glipizide. Asian Journal of Pharmaceutical Sciences, 4(4), 129135.
7. Ghosh, P., & Patel, K. (2012). Solid dispersion of glipizide for improved dissolution. International Journal of Pharmaceutical Sciences Review and Research, 17(2), 2832.
8. Singh, K. K., & Kumar, P. (2014). Enhanced dissolution and bioavailability of glipizide through selfmicroemulsifying drug delivery system (SMEDDS). Journal of Drug Delivery Science and Technology, 24(6), 620626.
9. Mottin, C., & Morselli, P. (2004). Glipizide: A Review of Its Pharmacokinetics and Clinical Efficacy in Type 2 Diabetes. Expert Opinion on Pharmacotherapy, 5(1), 7987.
10. Savjani, K. T., Gajjar, A. K., & Savjani, J. K. (2012). Drug solubility: Importance and enhancement techniques. ISRN Pharmaceutics, 2012, Article ID 195727. https://doi.org/10.5402/2012/195727.
11. Patel, R. M., & Patel, A. (2016). Solubility enhancement of a poorly water-soluble drug using solid dispersion technique: A review. Journal of Pharmacy Research, 9(3), 101105.
12. Kumar, S., Nanda, A., & Sharma, P. (2013). Techniques for solubility enhancement of poorly soluble drugs: An overview. Journal of Advanced Pharmacy Education & Research, 3(4), 427439.
13. Kesisoglou, F., & Panmai, S. (2007). Nanosizing—oral formulation development and biopharmaceutical evaluation. Advanced Drug Delivery Reviews, 59(7), 631644.
14. Kalepu, S., & Nekkanti, V. (2015). Insoluble drug delivery strategies: Review of recent advances and business prospects. Acta Pharmaceutica Sinica B, 5(5), 442453.
15. Dixit, R. P., & Puthli, S. P. (2009). Oral strip technology: Overview and future potential. Journal of Controlled Release, 139(2), 94107.
16. Savjani, K. T., Gajjar, A. K., & Savjani, J. K. (2012). Drug solubility: Importance and enhancement techniques. ISRN Pharmaceutics. https://doi.org/10.5402/2012/195727.
17. Liversidge, G. G., & Cundy, K. C. (1995). Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. International Journal of Pharmaceutics, 125(1), 9197.
18. Yu, L. (2001). Polymorphism in pharmaceutical solids. Advanced Drug Delivery Reviews, 48(1), 2742.
19. Childs, S. L., Stahly, G. P., & Park, A. (2007). The influence of cocrystal formation on the improvement of drug properties. Journal of Pharmaceutical Sciences, 96(3), 646660.
20. Chowdary KPR, Rao YS. Complexation with beta cyclodextrin to enhance the solubility and dissolution rate of glipizide. Indian J Pharm Sci. 2003;65(3):250255.
21. Patel HM, Patel NM. Formulation and optimization of glipizideβCD inclusion complex to enhance dissolution and bioavailability. Int J Pharm Sci Res. 2011;2(9):24062412.
22. Pawar AR, Shirsath GN. Enhancement of solubility of glipizide using solid dispersion technique. J Pharm Res. 2012;5(5):24232426.
23. Patel HM, Patel NM. Formulation and optimization of glipizideβCD inclusion complex to enhance dissolution and bioavailability. Int J Pharm Sci Res. 2011;2(9):24062412.
24. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145160.
25. Yalkowsky, S.H. (1999). Solubility and Solubilization in Aqueous Media. American Chemical Society,
26. Badwan, A., ElKhordagui, L.K., Saleh, A.M., & Khalil, S.A. (1983). The solubility of benzodiazepines in sodium salicylate solution and a model for hydrotropic solubilization. International Journal of Pharmaceutics, 13(1), 6774.
27. Smith, J., & Brown, A. (2021). "Comparative Effectiveness of Traditional vs. Modern Methods in [Field]." Journal of Technology and Innovation, 12(4), 567578.
28. Johnson, L. (2022). "Navigating Regulatory Challenges in Modern Technology Adoption." Regulatory Affairs Review, 19(2), 4562.
29. Davis, R., & Lee, M. (2023). "Practical Challenges in Implementing Hybrid Approaches." Case Studies in Operational Efficiency, 8(3), 234250.
30. Patel, D., et al. (2016). "Nanocrystal technology to enhance solubility and bioavailability of glipizide." International Journal of Pharmaceutics, 498(12), 4250.
31. Shah, N., et al. (2018). "Amorphous solid dispersions of glipizide for solubility enhancement." Drug Delivery and Translational Research, 8(3), 685696.
32. Sharma, P., et al. (2020). "Self-nanoemulsifying drug delivery system for improved solubility and bioavailability of glipizide." Journal of Drug Delivery Science and Technology, 58, 101705.

33. Chaudhary, A., et al. (2014). "Supercritical fluid technology for solubility enhancement of glipizide." Asian Journal of Pharmaceutics, 8(2), 103110.
34. Raghavendra, G. N., et al. (2019). "Glipizide saccharin cocrystals for solubility enhancement." Journal of Pharmaceutical Sciences, 108(10), 34533461.

How to cite this article:
Sanskruti Talele et al. Ijppr.Human, 2025; Vol. 31 (4): 307-318.

Conflict of Interest Statement: All authors have nothing else to disclose.

	Author Name – Sanskruti Rajendra Talele Student Department of Pharmaceutical Chemistry MET Institute of D. Pharmacy, Adgaon, Nashik, Maharashtra, India.
	Author Name: Pratiksha Rajaram Nathe Student Department of Pharmaceutical Chemistry MET Institute of D. Pharmacy, Adgaon, Nashik, Maharashtra, India.
	Author Name: Sakshi Sanjay Bacchav Student Department of Pharmaceutical Chemistry MET Institute of D. Pharmacy, Adgaon, Nashik, Maharashtra, India.
	Author Name: Pranav Santosh Pajai Student Department of Pharmaceutical Chemistry MET Institute of D. Pharmacy, Adgaon, Nashik, Maharashtra, India.

Author Name: Vedant Popat Thakare

Student

Department of Pharmaceutical Chemistry MET Institute of D. Pharmacy, Adgaon, Nashik, Maharashtra, India.